Search for other works by this author on: ...

Ariel University, Ari'el, Israel.

Telix Pharmaceuticals announced that TLX101 (131 I-iodofalan) increased median overall survival (OS) for patients with high-grade glioma, when compared against median OS without the drug. In the phase ...

10Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China. 11National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

Copyright held by the owner/author(s).

1Department of Microbiology, Immunology, and Cancer Biology, University of Virginia, Charlottesville, Virginia.

Novartis announced it will spend $23 billion to construct and expand facilities in the United States. The planned investment includes six new manufacturing plants, including two radioligand therapy ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...

Bengaluru, India–based Biocon Biologics announced today that bevacizumab-nwgd (Jobevne), a biosimilar of bevacizumab (Avastin; Genentech), was approved by the FDA. Bevacizumab, which is given ...

1Biomarkers and Clonal Dynamics Group, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain.

Copyright held by the owner/author(s).